文献速递消化系统肿瘤

胃癌患者腹膜细胞学肿瘤阳性与不良结局相关:一项全国性研究

Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.
PubMed 文献 · Eur J Cancer · 2024-01-15

这项荷兰全国性队列研究纳入2016—2021年诊断的cT1-4、cN0-2、M0或同时性腹膜转移胃癌患者共4397例,评估分期腹腔镜细胞学检查频率、CYT+患病率及总生存。CYT+患病率为8%,CYT+患者总生存与PM+患者同样不良,且显著差于PM-患者;CYT+患者中全身化疗与手术切除未见生存差异。

要点

  • 4397例胃癌患者中,40%(863/1745)在分期腹腔镜后接受细胞学评估,CYT+患病率为8%。
  • CYT+患者69例(1.6%),总生存与PM+患者相当(HR 0.86,95%CI 0.64-1.17,P=0.338)。
  • PM-较PM+总生存显著更好(HR 0.43,95%CI 0.38-0.49,P<0.001)。

核心结论

  • 在这项全国性研究中,胃癌CYT+患者的总生存与PM+患者同样不良,且显著差于PM-患者。
  • 最佳治疗策略尚未确立。

研究设计与样本

  • 荷兰全国性队列研究,数据来自荷兰癌症登记数据库并链接全国病理数据库。
  • 纳入2016—2021年诊断的cT1-4、cN0-2、M0或同时性腹膜转移胃癌患者,共4397例。

主要发现

  • 4397例患者中40%(863/1745)在分期腹腔镜后接受细胞学评估。
  • CYT+患病率为8%;CYT+患者69例(1.6%),PM+患者789例(17.9%),PM-患者3539例(80.5%)。
  • CYT+ versus PM+的总生存HR为0.86(95%CI 0.64-1.17,P=0.338)。
  • PM- versus PM+的总生存HR为0.43(95%CI 0.38-0.49,P<0.001)。
  • CYT+患者中全身化疗与手术切除之间未发现生存差异。

临床怎么用

  • 原文未据此给出推荐;作者指出CYT+胃癌的最佳治疗策略尚未确立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical significance of tumor-positive peritoneal cytology (CYT+) in gastric cancer (GC) patients is unclear. This nationwide cohort study aimed to i) assess the frequency of cytological analysis at staging laparoscopy; ii) determine the prevalence of CYT+GC; and iii) compare overall survival (OS) in CYT+ patients versus those with (PM+) and those without (PM-) macroscopic peritoneal disease. METHODS: All patients diagnosed with cT1-4, cN0-2 and M0 or synchronous PM GC between 2016-2021 were identified in the Netherlands Cancer Registry database and linked to the nationwide pathology database. RESULTS: A total of 4397 patients was included, of which 40 % underwent cytological assessment following staging laparoscopy (863/1745). The prevalence of CYT+ was 8 %. A total of 69 patients had CYT+(1.6 %), 789 (17.9 %) had PM+ and 3539 (80.5 %) had PM- disease. Hazard ratio for OS in CYT+ versus PM+ was 0.86 (95 %CI 0.64-1.17, p-value=0.338), and in PM- versus PM+0.43 (95 %CI 0.38-0.49, p-value<0.001). No survival difference was found between systemic chemotherapy versus surgical resection in CYT+ patients. DISCUSSION: In this nationwide study, OS for gastric cancer patients with CYT+ was equally unfavorable as for those with PM+ and significantly worse as compared to those with PM-. The optimal treatment strategy has yet to be established.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Van Der Sluis K, Taylor SN, Kodach LL, et al. Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study. Eur J Cancer. 2024. PMID: 38237371. doi:10.1016/j.ejca.2024.113541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。